|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Davis George Eric |
VP, General Counsel |
|
2008-06-16 |
4 |
D |
$33.89 |
$78,388 |
D/D |
(2,313) |
13,494 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-06-16 |
4 |
OE |
$7.84 |
$78,400 |
D/D |
10,000 |
15,807 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-06-05 |
4 |
AS |
$39.00 |
$117,000 |
D/D |
(3,000) |
3,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-06-05 |
4 |
OE |
$6.46 |
$19,380 |
D/D |
3,000 |
6,567 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-06-04 |
4 |
AS |
$37.30 |
$49,826 |
D/D |
(1,323) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-06-04 |
4 |
OE |
$6.13 |
$20,081 |
D/D |
1,323 |
1,323 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2008-06-02 |
4 |
AS |
$37.57 |
$677,367 |
D/D |
(18,000) |
160,804 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2008-06-02 |
4 |
OE |
$4.00 |
$64,000 |
D/D |
16,000 |
178,804 |
|
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2008-05-30 |
4 |
AS |
$38.29 |
$400,890 |
D/D |
(10,428) |
37,534 |
|
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2008-05-30 |
4 |
OE |
$22.00 |
$253,616 |
D/D |
11,528 |
47,962 |
|
- |
|
Baffi Robert |
SVP, Technical Operatons |
|
2008-05-30 |
4 |
AS |
$38.62 |
$42,586 |
D/D |
(1,100) |
36,434 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-05-21 |
4 |
AS |
$38.84 |
$65,158 |
D/D |
(1,667) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-05-21 |
4 |
OE |
$6.37 |
$20,267 |
D/D |
1,667 |
1,667 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-15 |
4 |
S |
$39.10 |
$195,546 |
D/D |
(5,000) |
3,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-15 |
4 |
OE |
$6.46 |
$32,300 |
D/D |
5,000 |
8,567 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-05-13 |
4 |
S |
$39.10 |
$391,252 |
D/D |
(10,000) |
5,807 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2008-05-13 |
4 |
OE |
$11.74 |
$117,400 |
D/D |
10,000 |
15,807 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-12 |
4 |
S |
$39.15 |
$195,791 |
D/D |
(5,000) |
3,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-12 |
4 |
OE |
$6.46 |
$32,300 |
D/D |
5,000 |
16,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-09 |
4 |
S |
$38.39 |
$310,031 |
D/D |
(8,000) |
8,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-09 |
4 |
OE |
$6.46 |
$51,680 |
D/D |
8,000 |
11,567 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev. |
|
2008-05-06 |
4 |
S |
$37.75 |
$611,550 |
D/D |
(16,200) |
28,665 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev. |
|
2008-05-06 |
4 |
OE |
$7.16 |
$142,348 |
D/D |
12,205 |
48,665 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-05 |
4 |
AS |
$36.53 |
$182,729 |
D/D |
(5,000) |
3,567 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-05-05 |
4 |
OE |
$6.46 |
$32,300 |
D/D |
5,000 |
26,120 |
|
- |
|
1303 Records found
|
|
Page 42 of 53 |
|
|